Table 1.
Bisphosphonates | Raloxifene/calcitonin | |
---|---|---|
N | 17,028 | 16,787 |
Demographic factors | ||
Age, years, | ||
mean (SD) | 79.9 (6.5) | 80.0 (6.9) |
Race, White | 16,180 (95) | 15,987 (95.2) |
Sex, female | 16,474 (96.8) | 16,244 (96.8) |
Health care utilization | ||
No. of visit, | ||
mean (SD) | 10.6 (6) | 10.5 (6.1) |
ER visit | 4,505 (26.5) | 4,482 (26.7) |
No. of all prescription drugs, mean (SD) | 10.4 (6) | 10.5 (6.1) |
Hospitalization | 6,089 (35.8) | 6,146 (36.6) |
Nursing home resident | 1,882 (11.1) | 1,991 (11.9) |
Comorbidities | ||
Prior fall | 2,094 (12.3) | 2,119 (12.6) |
Prior hip fracture | 612 (3.6) | 601 (3.6) |
Prior vertebral fracture | 1,858 (10.9) | 1,890 (11.3) |
BMD test | 4,085 (24) | 4,180 (24.9) |
Hypertension | 11,303 (66.4) | 11,233 (66.9) |
Chronic kidney disease | 492 (2.9) | 481 (2.9) |
Chronic liver disease | 207 (1.2) | 191 (1.1) |
Parkinson’s disease | 586 (3.4) | 598 (3.6) |
Dementia | 1,039 (6.1) | 1,092 (6.5) |
Diabetes mellitus | 4,354 (25.6) | 4,312 (25.7) |
Congestive heart failure | 3,664 (21.5) | 3,728 (22.2) |
COPD | 4,782 (28.1) | 4,763 (28.4) |
Inflammatory arthritis | 1,267 (7.4) | 1,258 (7.5) |
Inflammatory bowel disease | 241 (1.4) | 226 (1.4) |
Alcoholism | 311 (1.8) | 301 (1.8) |
Comorbidity Index, mean (SD) | 1.9 (1.9) | 2 (1.9) |
Other medications | ||
Opioids | 6,817 (40) | 6,826 (40.7) |
Anti-epileptics | 892 (5.2) | 877 (5.2) |
Proton pump inhibitors | 4,361 (25.6) | 4,441 (26.5) |
Benzodiazepines | 4,636 (27.2) | 4,614 (27.5) |
SSRI | 2,654 (15.6) | 2,683 (16) |
Warfarin | 1,814 (10.7) | 1,786 (10.6) |
Inhaled steroid | 1,389 (8.2) | 1,391 (8.3) |
Oral steroid | 2,420 (14.2) | 2,387 (14.2) |
New Jersey and Pennsylvania combined, 2nd drug dispensing and a 90-day lag period are required.
Data are presented in number (%), unless specified.
SD: standard deviation, ER: emergency room, BMD: bone mineral density, COPD: chronic obstructive pulmonary disease, SSRI: selective serotonin reuptake inhibitor